← Back to headlines
Novo Nordisk Secures $2.1 Billion Deal for Obesity Pill Development
Novo Nordisk has signed a $2.1 billion agreement aimed at developing more effective oral medications for obesity.
25 Feb, 13:00 — 25 Feb, 13:00
Sources
Showing 1 of 1 sources
